Table 2. Cox proportional hazard models for all-cause mortality introducing achieved HbA1c, SBP, and LDL-C as post-index mean values.
Patient number | Mortality rate (per 1000 person-years) | Model 1 | Model 2 | |||
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |||
HbA1c (%)* | ||||||
<6.0 | 444 | 41.7 | 1.37 (1.14–1.64) | <0.001 | 1.43 (1.19–1.71) | <0.001 |
6.0–7.0 | 2665 | 20.9 | 0.88 (0.79–0.99) | 0.034 | 0.95 (0.85–1.07) | 0.4 |
7.0–8.0 | 4187 | 14.3 | 0.68 (0.61–0.75) | <0.001 | 0.69 (0.62–0.77) | <0.001 |
8.0–9.0 | 2758 | 18.0 | 0.83 (0.74–0.93) | 0.002 | 0.82 (0.73–0.92) | 0.001 |
9.0–10.0 | 1408 | 17.2 | 0.98 (0.84–1.13) | 0.8 | 0.91 (0.78–1.05) | 0.20 |
≥10.0 | 1181 | 22.3 | 1.50 (1.30–1.74) | <0.001 | 1.44 (1.24–1.67) | <0.001 |
SBP (mmHg)* | ||||||
<120 | 834 | 15.9 | 1.06 (0.86–1.32) | 0.6 | 1.14 (0.92–1.42) | 0.23 |
120–130 | 3182 | 18.9 | 1.06 (0.94–1.20) | 0.33 | 1.10 (0.98–1.25) | 0.12 |
130–140 | 4617 | 16.6 | 0.66 (0.60–0.72) | <0.001 | 0.80 (0.72–0.90) | <0.001 |
140–150 | 2692 | 18.8 | 0.84 (0.74–0.96) | 0.009 | 0.85 (0.75–0.97) | 0.014 |
150–160 | 941 | 21.6 | 1.14 (0.95–1.36) | 0.17 | 1.06 (0.88–1.27) | 0.6 |
≥160 | 377 | 20.1 | 1.15 (0.85–1.54) | 0.4 | 1.10 (0.82–1.48) | 0.5 |
LDL-C (mg/dL)* | ||||||
<70 | 676 | 33.7 | 1.30 (1.11–1.53) | 0.001 | 1.19 (1.01–1.40) | 0.038 |
70–100 | 3604 | 19.6 | 0.80 (0.72–0.89) | <0.001 | 0.80 (0.72–0.89) | <0.001 |
100–130 | 6051 | 14.1 | 0.81 (0.72–0.90) | <0.001 | 0.68 (0.61–0.75) | <0.001 |
130–160 | 1806 | 19.5 | 0.94 (0.82–1.06) | 0.31 | 1.00 (0.87–1.13) | 0.9 |
≥160 | 506 | 31.9 | 1.56 (1.30–1.86) | <0.001 | 1.56 (1.30–1.86) | <0.001 |
The models used Cox proportional hazards regression analyses adjusted for potential confounders. The hazard ratios relative to the population mean were calculated.
*HbA1c, SBP, and LDL-C were calculated as the mean of any values recorded between the index date and death or censor.
Model 1 adjusted for age and sex.
Model 2 included the confounders in model 1, plus pre-existing myocardial infarction, congestive heart failure, stroke, malignant neoplasm, chronic kidney disease, use of insulin, any anti-hypertensive drug, any lipid-lowering drug, and antiplatelet.